ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average rating of “Buy” by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $80.13.

Several analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price on the stock. Truist Financial raised their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. Finally, Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 target price on the stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $70.82 on Thursday. The stock has a fifty day moving average price of $64.94 and a 200 day moving average price of $60.14. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $72.57. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market cap of $1.54 billion, a PE ratio of -128.76 and a beta of 0.49.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock worth $197,792 in the last three months. Corporate insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Exchange Traded Concepts LLC grew its holdings in ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after buying an additional 310 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock worth $582,000 after purchasing an additional 364 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after purchasing an additional 412 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of ANI Pharmaceuticals by 2.3% during the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock valued at $1,028,000 after buying an additional 417 shares during the period. Finally, US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.